PTCT (PTC Therapeutics) Cyclically Adjusted Book per Share: $1.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTCT PTC Therapeutics Inc PTCT
62 GF Score
Price $72.65
GF Value $37.54
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is PTC Therapeutics Cyclically Adjusted Book per Share?

PTC Therapeutics PTCT -1.44% 62 Cyclically Adjusted Book per Share is $1.06 as of Jun. 2026. GuruFocus rates PTCT with a GF Score™ of 62/100 and a GF Value™ of $37.54 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

PTC Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was $-1.985. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.06 for the trailing ten years ended in Jun. 2026.

During the past 12 months, PTC Therapeutics's average Cyclically Adjusted Book Growth Rate was -49.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of PTC Therapeutics was -25.40% per year. The lowest was -37.80% per year. And the median was -31.60% per year.

As of today (2026-08-12), PTC Therapeutics's current stock price is $72.65. PTC Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $1.06. PTC Therapeutics's Cyclically Adjusted PB Ratio of today is 68.54.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PTC Therapeutics was 80.05. The lowest was 3.43. And the median was 8.08.


PTC Therapeutics  (NAS:PTCT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PTC Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=72.65/1.06
=68.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PTC Therapeutics was 80.05. The lowest was 3.43. And the median was 8.08.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


PTC Therapeutics Cyclically Adjusted Book per Share Related Terms


PTC Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Cyclically Adjusted Book per Share Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.46 6.20 4.91 2.68 1.49

PTC Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 1.78 1.49 1.26 1.06

PTCT vs XENE, CGON, ERAS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted PB Ratio falls into.


PTCT
62GF Score
PTC Therapeutics Inc PTCT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PTC Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.985/333.9520*333.9520
=-1.985

Current CPI (Jun. 2026) = 333.9520.

PTC Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.103 241.428 5.675
201612 3.500 241.432 4.841
201703 2.938 243.801 4.024
201706 4.109 244.955 5.602
201709 3.518 246.819 4.760
201712 3.759 246.524 5.092
201803 3.595 249.554 4.811
201806 5.728 251.989 7.591
201809 7.656 252.439 10.128
201812 6.931 251.233 9.213
201903 8.780 254.202 11.535
201906 8.324 256.143 10.853
201909 10.777 256.759 14.017
201912 9.596 256.974 12.471
202003 8.425 258.115 10.900
202006 8.514 257.797 11.029
202009 7.535 260.280 9.668
202012 6.913 260.474 8.863
202103 4.156 264.877 5.240
202106 2.786 271.696 3.424
202109 1.485 274.310 1.808
202112 0.020 278.802 0.024
202203 -1.270 287.504 -1.475
202206 -2.548 296.311 -2.872
202209 -3.158 296.808 -3.553
202212 -4.748 296.797 -5.342
202303 -6.182 301.836 -6.840
202306 -7.691 305.109 -8.418
202309 -8.890 307.789 -9.646
202312 -10.812 306.746 -11.771
202403 -11.662 312.332 -12.469
202406 -12.746 314.175 -13.548
202409 -13.701 315.301 -14.511
202412 -14.131 315.605 -14.952
202503 -2.345 319.799 -2.449
202506 -2.602 322.561 -2.694
202509 -1.949 324.800 -2.004
202512 -2.520 324.054 -2.597
202603 -2.177 330.213 -2.202
202606 -1.985 333.952 -1.985

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.06 mean?
PTC Therapeutics (PTCT) has a Cyclically Adjusted Book per Share of $1.06 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Cyclically Adjusted Book per Share too high?
PTC Therapeutics' current Cyclically Adjusted Book per Share is $1.06. Overall, PTC Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Cyclically Adjusted Book per Share compare to XENE and CGON?
PTC Therapeutics' Cyclically Adjusted Book per Share of $1.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Cyclically Adjusted Book per Share is $1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, PTC Therapeutics (PTCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.54, compared to a current price of $72.65 — trading 93.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.06. PTC Therapeutics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For PTC Therapeutics (PTCT), the current Cyclically Adjusted Book per Share is $1.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (PTCT) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of $72.65 is trading 93.5% above its estimated GF Value™ of $37.54. GuruFocus considers PTC Therapeutics to be Significantly Overvalued.

Key valuation signals for PTCT:

  • Cyclically Adjusted Book per Share: $1.06
  • GF Value™: $37.54 vs. price of $72.65 (93.5% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the PTCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges BH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
62GF Score

Get the complete analysis for PTCT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.65
Price
$37.54
GF Value